Novo Nordisk CEO Lars Fruergaard Jørgensen will step down amid market challenges and a clinical disappointment for CagriSema.

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for ...

RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored ...

A Delaware jury on Thursday said Regeneron should get more than $400 million in damages in its long-running antitrust case ...

The comments come just a couple months after the company slashed its 2027 sales expectations for the Biogen-partnered ...

Vinay Prasad may have just started as the new director of the FDA's biologics center, but he's 'planning to unleash a massive ...

The FDA’s drug promotion office is calling out Australia's Mayne Pharma for making “false or misleading claims” about the ...

Bristol Myers Squibb CEO Chris Boerner said America’s role as the global biopharma leader is at a 'pivot point' as the Trump ...